RT Journal Article SR Electronic T1 Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 262 OP 269 DO 10.21873/invivo.13076 VO 37 IS 1 A1 CHIEN-LIANG LIU A1 SHIH-PING CHENG A1 WEN-CHIEN HUANG A1 MING-JEN CHEN A1 CHI-HSIN LIN A1 SHAN-NA CHEN A1 YUAN-CHING CHANG YR 2023 UL http://iv.iiarjournals.org/content/37/1/262.abstract AB Background/Aim: A recent study suggested that solute carrier family 35 member A2 (SLC35A2) is related to poor prognosis in patients with breast cancer. SLC35A2 transports uridine diphosphate-galactose from the cytosol to the lumen of the endoplasmic reticulum and Golgi. Materials and Methods: Immunohistochemical expression of SLC35A2 was evaluated using tissue microarrays. Cell growth, migration, and invasion of breast cancer cells were examined following loss- and gain-of-expression of SLC35A2. Results: Normal breast tissue exhibited SLC35A2 immunoreactivity in the nucleus. A progressive increase in cytoplasmic expression from in situ carcinoma to invasive carcinoma was observed. There was a correlation between cytoplasmic SLC35A2 expression and breast cancer stage (p<0.001). MDA-MB-468 and MCF-7 cells transfected with SLC35A2 shRNA had unchanged cell viability but significantly reduced cell migration and invasion. In contrast, MDA-MB-231 and HCC1806 cells transfected with the SLC35A2 expression vector showed increased migration. Conclusion: Breast cancer progression is accompanied by differential expression patterns of SLC35A2. The migratory or invasive capacity of breast cancer cells is associated with SLC35A2 expression.